2/5
05:15 pm
iova
Best-in-Class Real-World Data Support Early Amtagvi® Treatment in Advanced Melanoma
Medium
Report
Best-in-Class Real-World Data Support Early Amtagvi® Treatment in Advanced Melanoma
2/5
08:04 am
iova
Iovance Biotherapeutics (NASDAQ:IOVA) had its "sell" rating reaffirmed by analysts at The Goldman Sachs Group, Inc..
Medium
Report
Iovance Biotherapeutics (NASDAQ:IOVA) had its "sell" rating reaffirmed by analysts at The Goldman Sachs Group, Inc..
1/16
05:15 pm
iova
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Medium
Report
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
1/16
05:31 am
iova
Iovance Biotherapeutics (IOVA) Is Down 14.9% After Governance Scrutiny And Equity Raise Plan Is Revealed [Yahoo! Finance]
Medium
Report
Iovance Biotherapeutics (IOVA) Is Down 14.9% After Governance Scrutiny And Equity Raise Plan Is Revealed [Yahoo! Finance]
1/15
11:53 pm
iova
Iovance Biotherapeutics (IOVA) Valuation Check After Amtagvi Outlook Reaffirmation And Governance Concerns [Yahoo! Finance]
Medium
Report
Iovance Biotherapeutics (IOVA) Valuation Check After Amtagvi Outlook Reaffirmation And Governance Concerns [Yahoo! Finance]
1/15
02:36 pm
iova
Iovance Biotherapeutics, Inc. (IOVA): A Bull Case Theory [Yahoo! Finance]
Low
Report
Iovance Biotherapeutics, Inc. (IOVA): A Bull Case Theory [Yahoo! Finance]
1/12
03:31 pm
iova
Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of Iovance Biotherapeutics, Inc. (IOVA), Nutex Health, Inc. (NUTX), Lantheus Holdings, Inc. (LNTH), and Molina Healthcare, Inc. (MOH)
Low
Report
Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of Iovance Biotherapeutics, Inc. (IOVA), Nutex Health, Inc. (NUTX), Lantheus Holdings, Inc. (LNTH), and Molina Healthcare, Inc. (MOH)
12/31
11:21 am
iova
Barclays Adjusts Valuation Targets for Iovance Biotherapeutics (IOVA) Amid Biotech Sector Review [Yahoo! Finance]
Neutral
Report
Barclays Adjusts Valuation Targets for Iovance Biotherapeutics (IOVA) Amid Biotech Sector Review [Yahoo! Finance]
12/29
12:52 am
iova
Iovance Biotherapeutics: Bright Prospects For 2026 [Seeking Alpha]
Low
Report
Iovance Biotherapeutics: Bright Prospects For 2026 [Seeking Alpha]
12/24
06:15 am
iova
Iovance Biotherapeutics (NASDAQ:IOVA) was upgraded by analysts at Barclays PLC to a "strong-buy" rating.
Low
Report
Iovance Biotherapeutics (NASDAQ:IOVA) was upgraded by analysts at Barclays PLC to a "strong-buy" rating.
12/19
05:15 pm
iova
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
High
Report
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
12/17
07:06 am
iova
Iovance Biotherapeutics (NASDAQ:IOVA) had its "overweight" rating reaffirmed by analysts at Barclays PLC.
High
Report
Iovance Biotherapeutics (NASDAQ:IOVA) had its "overweight" rating reaffirmed by analysts at Barclays PLC.
11/24
07:19 am
iova
Iovance Biotherapeutics (NASDAQ:IOVA) had its "overweight" rating reaffirmed by analysts at Barclays PLC.
High
Report
Iovance Biotherapeutics (NASDAQ:IOVA) had its "overweight" rating reaffirmed by analysts at Barclays PLC.
11/21
05:15 pm
iova
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
High
Report
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
11/12
03:15 pm
iova
Down 75% in 12 Months, Can Iovance Biotherapeutics Stock Turn Things Around? [Yahoo! Finance]
Neutral
Report
Down 75% in 12 Months, Can Iovance Biotherapeutics Stock Turn Things Around? [Yahoo! Finance]
11/11
01:33 pm
iova
Iovance Biotherapeutics: Base-Case Q3 Report Keeps 'Show Me' Mode [Seeking Alpha]
Low
Report
Iovance Biotherapeutics: Base-Case Q3 Report Keeps 'Show Me' Mode [Seeking Alpha]
11/7
07:07 pm
iova
Is Iovance Biotherapeutics (IOVA) Undervalued? A Fresh Look at Valuation After Recent Share Price Rebound [Yahoo! Finance]
Low
Report
Is Iovance Biotherapeutics (IOVA) Undervalued? A Fresh Look at Valuation After Recent Share Price Rebound [Yahoo! Finance]